Cart
sales@molnova.com
DW71177
CAS No. 2241311-72-6
DW71177( —— )
Catalog No. M37566 CAS No. 2241311-72-6
DW71177 is a bd1-selective and potent BET inhibitor with potent anti-leukemic activity for the study of leukemia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 296 | Get Quote |
|
| 5MG | 459 | Get Quote |
|
| 10MG | 657 | Get Quote |
|
| 25MG | 994 | Get Quote |
|
| 50MG | 1371 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameDW71177
-
NoteResearch use only, not for human use.
-
Brief DescriptionDW71177 is a bd1-selective and potent BET inhibitor with potent anti-leukemic activity for the study of leukemia.
-
DescriptionDW71177 is a novel [1,2,4]triazolo[4,3-a] quinoxaline-based potent and BD1-Selective BET inhibitor, and can be used for study of acute myeloid leukemia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2241311-72-6
-
Formula Weight384.48
-
Molecular FormulaC20H28N6O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NCCCCNC1=NC=2C=C(OC)C=CC2N3C1=NN=C3C)CC(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ali I, et al. DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia. Eur J Med Chem. Published online December 16, 2023.?
molnova catalog
related products
-
MS645
MS645 is an inhibitor of bromodomain-containing protein 4 (BRD4) with a Ki of 18.4 nM for BRD4-BD1/BD2.
-
J147
J-147 is a broad spectrum neuroprotective phenyl hydrazide compound(EC50=60-115 nM) with significant neurotrophic properties related to the induction of brain-derived neurotrophic factor (BDNF).
-
Y06137
Y06137 is an effective and selective BET inhibitor with a Kd of 81 nM for BRD4(1) bromodomain. Y06137 can be used for research on the treatment of castration-resistant prostate cancer.
